On July 3, China’s National Medical Products Administration (NMPA) officially approved Gensci Pharma’s Class 1 innovative drug—fusincimab (brand name: Jinbeixin®). As China’s first independently ...
When dry eye patients suffer from recurring dryness and stinging, the launch of a new drug could be the key to transforming their quality of life. Recently, a major milestone emerged in China’s dry ...
Seizing industry development opportunities to provide higher-quality services to clients, Becoming an outstanding partner for innovative Chinese pharmaceutical companies.Jiang Long believes the Chines...
Flexible Biometrics Resources That Scale With Your NeedsGCP ClinPlus' Functional Service Provider (FSP) model delivers specialized biometrics expertise that seamlessly integrates with your organiz...
